We present a case series of atrophic dermatofibrosarcoma protuberans (DFSP) to further characterise its clinical and pathological features. Sixteen cases were enrolled in the study. There were five males and 11 females with a median age of 28 years. The vast majority occurred in the trunk (12/16, 75%), whereas a minority involved the upper limb or limb gird (2/16, 12.5%), and head and neck region (2/16, 12.5%). The most common presentation was a depressed plaque-like lesion with a greyish-red to purplish-blue colour. Histologically, the lesion was dermal-based consisting of monomorphous spindle cells arranged in parallel fascicles with focal areas displaying storiform architecture. In addition, one case showed remarkable hyalinisation of the matrix, two cases contained scattered pigmented dendritic cells and one case had admixed giant cell fibroblastoma-like component, respectively. The diagnosis was confirmed by immunohistochemical study, and by further fluorescence in situ hybridisation analysis in six cases. Follow-up thus far has revealed a relatively low rate of local recurrence (1/10, 10%). Familiarity with the distinctive clinical and pathological features of atrophic DFSP helps avoid misdiagnosis. Like a classical DFSP, morphological variants can also occur in an atrophic DFSP, including pigmented, sclerosing and hybrid subtypes, albeit rare.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pathol.2019.06.002 | DOI Listing |
Heliyon
November 2024
Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.
Glob Pediatr Health
September 2024
Pediatric Plastic surgery Unit, Children's Hospital of Rabat, Morocco.
Cureus
July 2024
Department of Dermatology, Wan Fang Hospital, Taipei Medical University, Taipei, TWN.
J Cosmet Dermatol
May 2024
Department of Dermatology, International Mongolian Hospital of Inner Mongolia, Hohhot, China.
Brain Dev
January 2024
Department of Pediatric Surgery, National Hospital Organization Nagara Medical Center, Gifu, Japan.
Background: Spinal muscular atrophy (SMA) is a hereditary neuromuscular disorder characterized by skeletal muscle atrophy and weakness. New treatments for SMA have been developed namely, the drugs nusinersen, onasemnogene abeparvovec, and risdiplam. However, there are limited reports on their effects on adult patients with SMA, particularly over long periods.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!